Fingerprint
Dive into the research topics of 'Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design
Robert L Ferris, Hisham Mehanna, Jonathan D Schoenfeld, Makoto Tahara, Sue S Yom, Robert Haddad, André König, Pauline Witzler, Marcis Bajars, Christophe Le Tourneau*
*Corresponding author for this work
Research output: Contribution to journal › Review article › peer-review
13
Downloads
(Pure)